Background: In clinical trials to date, rimonabant, the first selectiveCB1receptor blocker improved multiple cardiometabolic risk factors. The Rimonabant Eating Behaviour Assessment (REBA) study examined the effect of rimonabant over 12 weeks on energy intake under controlled and free-living conditions. Methods: After 2-week’s run in, 156 obese patients (mean body mass index 36.5 kg/m2) were randomized to rimonabant 20 mg/day or placebo with/without a 600 kcal hypocaloric diet. Energy intake was assessed at Weeks 3/4 and 10/11 during controlled high- and low-fat meals, and by food diaries under free-living conditions. Motivation to eat and food behaviour were assessed by visual analogue scales, food preference forced choice tests, and End of Day Questionnaires. Results: Rimonabant 20 mg/day significantly reduced energy intake by 17% and 15.6% from baseline during high- and low-fat meals, respectively, at Weeks 3/4 (P = 0.011 and < 0.001 vs. placebo). Corresponding reductions at Weeks 10/11 were 23% and 16.7%(P = 0.002 and < 0.001 vs. placebo). Mean weight loss at last follow-up was greater with rimonabant 20 mg/day than placebo(-4.0 vs. -1.1 kg; P < 0.001). Effects on food intake were independent of food type and pleasantness. Rimonabant reduced pre-meal motivation to eat with no change in sensation of fullness or contentedness. There was no effect on macronutrient selection, food preferences, or hedonic evaluation of foods eaten during free-living assessments.Conclusions: Rimonabant 20 mg/day reduced total energy intake by overweight/obese patients during high- and low-fat meals, independent of normal or hypocaloric diet prescription.
|Number of pages||1|
|Issue number||Supplement 2|
|Early online date||15 Aug 2006|
|Publication status||Published - Sep 2006|